Teleflex to acquire Vascular Intervention business of BIOTRONIK for €760m.

Teleflex, a global provider of medical technology products, agreed to acquire Vascular Intervention business of BIOTRONIK, a multi-national cardiovascular biomedical research and technology company, for €760m. "We are excited to announce the acquisition of BIOTRONIK’s Vascular Intervention business, which we anticipate will significantly enhance our global presence in the cath lab, expand our suite of innovative technologies, and improve patient care. We believe the acquisition will allow us to position this advanced coronary portfolio alongside our existing Interventional business and establish our global footprint in the fast-growing peripheral intervention market," Liam Kelly, Teleflex Chairman, President and CEO.